T

Tong Ren Tang Technologies Co Ltd
SWB:TNG

Watchlist Manager
Tong Ren Tang Technologies Co Ltd
SWB:TNG
Watchlist
Price: 0.446 EUR -1.33%
Market Cap: €280.4m

Relative Value

The Relative Value of one TNG stock under the Base Case scenario is 0.73 EUR. Compared to the current market price of 0.446 EUR, Tong Ren Tang Technologies Co Ltd is Undervalued by 39%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

TNG Relative Value
Base Case
0.73 EUR
Undervaluation 39%
Relative Value
Price
T
Worst Case
Base Case
Best Case

Multiples Across Competitors

TNG Competitors Multiples
Tong Ren Tang Technologies Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Tong Ren Tang Technologies Co Ltd
SWB:TNG
5.5B EUR 0.7 11.4 1.7 1.7
US
Eli Lilly and Co
NYSE:LLY
989.4B USD 16.8 54.2 36.4 39
US
Johnson & Johnson
NYSE:JNJ
555.3B USD 5.9 20.6 14.3 17.6
CH
Roche Holding AG
SIX:ROG
280.6B CHF 4.6 29.7 12.6 14.7
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP 5.1 31.4 20.4 29.8
CH
Novartis AG
SIX:NOVN
224.2B CHF 5.1 19.8 15.8 20.4
US
Merck & Co Inc
NYSE:MRK
275.5B USD 4.4 14.7 10.4 12.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.7 10.9 12.7
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
150.4B USD 2.4 15.4 7.7 10.6
FR
Sanofi SA
PAR:SAN
97.5B EUR 1.7 8.2 7.7 7.7
P/E Multiple
Earnings Growth PEG
CN
T
Tong Ren Tang Technologies Co Ltd
SWB:TNG
Average P/E: 22.1
11.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.2
54%
1
US
Johnson & Johnson
NYSE:JNJ
20.6
6%
3.4
CH
Roche Holding AG
SIX:ROG
29.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
38%
0.8
CH
Novartis AG
SIX:NOVN
19.8
17%
1.2
US
Merck & Co Inc
NYSE:MRK
14.7
14%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
15.7
2%
7.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.4
27%
0.6
FR
Sanofi SA
PAR:SAN
8.2
1%
8.2
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
T
Tong Ren Tang Technologies Co Ltd
SWB:TNG
Average EV/EBITDA: 43.9
1.7
8%
0.2
US
Eli Lilly and Co
NYSE:LLY
36.4
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.3
2%
7.2
CH
Roche Holding AG
SIX:ROG
12.6
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
20.4
10%
2
CH
Novartis AG
SIX:NOVN
15.8
6%
2.6
US
Merck & Co Inc
NYSE:MRK
10.4
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
1%
10.9
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.7
0%
N/A
FR
Sanofi SA
PAR:SAN
7.7
8%
1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
T
Tong Ren Tang Technologies Co Ltd
SWB:TNG
Average EV/EBIT: 93.8
1.7
12%
0.1
US
Eli Lilly and Co
NYSE:LLY
39
37%
1.1
US
Johnson & Johnson
NYSE:JNJ
17.6
6%
2.9
CH
Roche Holding AG
SIX:ROG
14.7
6%
2.5
UK
AstraZeneca PLC
LSE:AZN
29.8
23%
1.3
CH
Novartis AG
SIX:NOVN
20.4
12%
1.7
US
Merck & Co Inc
NYSE:MRK
12.3
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.6
7%
1.5
FR
Sanofi SA
PAR:SAN
7.7
6%
1.3